SYRS
$4.33
Syros Pharmaceuticals
($.03)
(.69%)
SYRS
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.43)
Revenue:  $5.11 Mil
Thursday
Nov 4
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SYRS reports earnings?
Beat
Meet
Miss

Where is SYRS's stock price going from here?
Up
Flat
Down
Stock chart of SYRS
Analysts
Summary of analysts' recommendations for SYRS
Score
Grade
Pivots
Resistance
$4.64
$4.57
$4.45

$4.38

Support
$4.26
$4.19
$4.07
Tweet
Growth
Description
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.